|
May 6
|
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
|
|
Apr 30
|
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
|
|
Apr 24
|
Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?
|
|
Apr 3
|
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
|
|
Apr 2
|
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
|
|
Mar 27
|
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
|
|
Mar 26
|
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
|
|
Dec 15
|
11 Most Promising Biotech Stocks to Buy According to Analysts
|
|
Dec 12
|
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
|
|
Nov 6
|
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
|
|
Nov 5
|
With This Rally, Rocket Just Might Take Off
|
|
Nov 2
|
Rocket Pharmaceuticals Stock Sees Improved Price Strength
|
|
Oct 2
|
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
|
|
Sep 13
|
These Stocks Are Moving the Most Today: Apple, BP, Ford, NIO, Rocket Pharmaceuticals, and More
|
|
Sep 13
|
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
|
|
Sep 12
|
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
Sep 12
|
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
|
|
Sep 6
|
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
|
|
Aug 10
|
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
|